| answer text |
<p>Decisions on whether individual medicines are suitable for assessment by the National
Institute for Health and Care Excellence (NICE), and whether they meet the criteria
for the highly specialised technologies programme, are taken through an established
topic selection process.</p><p>The process is overseen by NICE and includes consideration
against published criteria by a topic selection panel and engagement with stakeholders.
Although NHS England, NHS Improvement and the Department provide input and are part
of this panel, the decision-making process is led by NICE. Kuvan for the treatment
of phenylketonuria was last considered by the topic selection panel on 15 February
2019.</p><p>In the absence of guidance from NICE, it is for National Health Service
organisations and healthcare professionals to make decisions on whether to fund Kuvan
on the basis of an assessment of the available evidence. Treatment for patients with
phenylketonuria who are not receiving Kuvan or for who Kuvan is not effective includes
dietary protein restriction combined with dietary supplements.</p><p> </p><p> </p><p><strong>
</strong></p><p><strong> </strong></p>
|
|
